|
1
|
Tatemoto K, Hosoya M, Habata Y, Fujii R,
Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C,
Kurokawa T, Onda H and Fujino M: Isolation and characterization of
a novel endogenous peptide ligand for the human APJ receptor.
Biochem Biophys Res Commun. 251:471–476. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleinz MJ, Skepper JN and Davenport AP:
Immunocytochemical localisation of the apelin receptor, APJ, to
human cardiomyocytes, vascular smooth muscle and endothelial cells.
Regul Pept. 126:233–240. 2005. View Article : Google Scholar
|
|
3
|
Cheng X, Cheng XS and Pang CC: Venous
dilator effect of apelin, an endogenous peptide ligand for the
orphan APJ receptor, in conscious rats. Eur J Pharmacol.
470:171–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishida J, Hashimoto T, Hashimoto Y,
Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R,
Shiota N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K,
Kasuya Y, Mochizuki N and Fukamizu A: Regulatory roles for APJ, a
seven-transmembrane receptor related to angiotensin-type 1 receptor
in blood pressure in vivo. J Biol Chem. 279:26274–26279.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katugampola SD, Maguire J, Matthewson SR
and Davenport AP: [125I]-(Pyr1)Apelin-13 is a
novel radioligand for localizing the APJ orphan receptor in human
and rat tissues with evidence for a vasoconstrictor role in man. Br
J Pharmacol. 132:1255–1260. 2001.
|
|
6
|
Hashimoto T, Kihara M, Ishida J, Imai N,
Yoshida S, Toya Y, Fukamizu A, Kitamura H and Umemura S: Apelin
stimulates myosin light chain phosphorylation in vascular smooth
muscle cells. Arterioscler Thromb Vasc Biol. 26:1267–1272. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cohn JN: Vascular wall function as a risk
marker for cardiovascular disease. J Hypertens Suppl. 17:41–44.
1999.PubMed/NCBI
|
|
8
|
Rubanyi GM: The role of endothelium in
cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol.
22(Suppl 4): S1–S14. 1993. View Article : Google Scholar
|
|
9
|
Baylis C, Mitruka B and Deng A: Chronic
blockade of nitric oxide synthesis in the rat produces systemic
hypertension and glomerular damage. J Clin Invest. 90:278–281.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartunek J, Weinberg EO, Tajima M,
Rohrbach S, Katz SE, Douglas PS and Lorell BH: Chronic
NG-nitro-L-arginine methyl ester-induced hypertension novel
molecular adaptation to systolic load in absence of hypertrophy.
Circulation. 101:423–429. 2000. View Article : Google Scholar
|
|
11
|
Dornas WC and Silva ME: Animal models for
the study of arterial hypertension. J Biosci. 36:731–737. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suda O, Tsutsui M, Morishita T, Tanimoto
A, Horiuchi M, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N and
Nakashima Y: Long-term treatment with Nω-nitro-l-arginine methyl
ester causes arteriosclerotic coronary lesions in endothelial
nitric oxide synthase-deficient. Circulation. 106:1729–1735.
2002.
|
|
13
|
Fukamizu A, Sugimura K, Takimoto E,
Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K and
Murakami K: Chimeric renin-angiotensin system demonstrates
sustained increase in blood pressure of transgenic mice carrying
both human renin and human angiotensinogen genes. J Biol Chem.
268:11617–11621. 1993.
|
|
14
|
Hobbs AJ and Gibson A:
L-NG-nitro-arginine and its methyl ester are potent
inhibitors of non-adrenergic, non-cholinergic transmission in the
rat anococcygeus. Br J Pharmacol. 100:749–752. 1990.
|
|
15
|
Widlansky ME, Gokce N, Keaney JF Jr and
Vita JA: The clinical implications of endothelial dysfunction. J Am
Coll Cardiol. 42:1149–1160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Norata GD, Pirillo A, Callegari E, Hamsten
A, Catapano AL and Eriksson P: Gene expression and intracellular
pathways involved in endothelial dysfunction induced by VLDL and
oxidised VLDL. Cardiovasc Res. 59:169–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nürnberger W, Michelmann I, Burdach S and
Göbel U: Endothelial dysfunction after bone marrow transplantation:
Increase of soluble thrombomodulin and PAI-1 in patients with
multiple transplant-related complications. Ann Hematol. 76:61–65.
1998.
|
|
18
|
De Gennaro Colonna V, Rossoni G, Rigamonti
A, Bonomo S, Manfredi B, Berti F and Muller E: Enalapril and
quinapril improve endothelial vasodilator function and aortic eNOS
gene expression in L-NAME-treated rats. Eur J Pharmacol. 450:61–66.
2002.PubMed/NCBI
|
|
19
|
Wang LY, Zhang DL, Zheng JF, Zhang Y,
Zhang QD and Liu WH: Apelin-13 passes through the ADMA-damaged
endothelial barrier and acts on vascular smooth muscle cells.
Peptides. 32:2436–2443. 2011. View Article : Google Scholar : PubMed/NCBI
|
